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It is a well established fact that the removal or injury of one
kidney results in renal growth of the other kidney [11. This
compensatory renal growth is controlled by a humoral serum
factor(s) which is induced by reduction of renal functions [2—5].
Therefore, this humoral factor, so-called renotropin or renotro-
pic growth factor, should also stimulate growth of the healthy
area of the physically injured or disease-bearing kidney in
addition to the other kidney.
In experimental animals the extent of renal growth is known
to be related directly to the portion of the kidney mass (partially
or subtotally) removed [61. Thus, the amount of renotropic
growth factor produced should be proportional to the amount of
renal function lost. In cancer-bearing kidneys, the enlargement
and infiltration of cancer in kidneys theoretically should pro-
duce the renotropic growth factor and stimulate healthy tissue
to grow. When a cancer-bearing kidney is removed, the lost
proportion of renal function should be responsible for the
amount of renotropic growth factor produced.
In this communication we demonstrate the renotropic growth
factor in renal cancer patient sera after uninephrectomy and an
assay procedure for renotropic growth factor using noncancer-
ous cells from a cancer-bearing kidney.
Methods
Preparation of serum. Sera from six cancer patients and two
kidney transplantation donors were studied. Diagnosis of the
cancer patients is shown in Table 1. The method of serum
isolation is discussed in another paper in this symposium issue
[7]. Sera were collected by venous puncture a few days before
and 5 days after nephrectomy. Postoperative day 5 was selected
for serum collection because the greatest stimulation of DNA
synthesis was found to occur at this time after uninephrectomy
[5, 71.
Cell culture and growth media. Two human primary culture
cell systems were prepared for assaying the growth-stimulating
factor. These primary human kidney (PHK) cell culture sys-
tems were generated from kidneys taken during nephrectomy of
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a patient with hydronephrosis and another patient with renal
adenocarcinoma. Healthy cortex area of the patient kidney
bearing renal hydronephrosis or adenocarcinoma was excised,
minced, and trypsinized with 0.25% trypsin as described by the
method of Gallagher [81. The trypsinized cells were plated in
minimum essential medium (MEM) supplemented with 20%
human serum. The second subcultures of these cells were used
for assaying growth-stimulating factor 17].
Assay for stimulation of DNA synthesis. Growth-stimulating
activity was assayed by 3H-thymidine incorporation into DNA
as described previously [5, 7].
Results
Growth-stimulating activity in various cancer patient sera.
As we reported, renotropic growth-stimulating activity in hu-
man sera reaches the maximum about day 5 after uninephrec-
tomy [7]. We, therefore, collected 5-day postnephrectomized
sera of various cancer patients and assayed them simultaneous-
ly for stimulation of DNA synthesis of PHK derived from a
hydronephrosis patient. As shown in Table I. 10% uninephrec-
tomized sera showed increased stimulation of DNA synthesis
over prenephrectomized sera in all patients. Sera of the first
three patients, numbered 1, 2, and 3, showed significant stimu-
lation of PHK cell growth (27 to 68% increase) after uninephrec-
tomy. Sera of the last three patients, numbered 4, 5, and 6,
stimulated PHK cell growth to a much greater extent (2.69- to
3.19-fold increase).
Variation in the increased growth-stimulating activity found
in these cancer patients after removal of cancer-bearing kidneys
is most probably due to different amounts of renal function loss.
This is because the amount of functional noncancerous cells in
each nephrectomized cancer patient kidney varies by the extent
of cancer cell infiltration.
Noncancerous cells in cancer-bearing kidneys sensitive to
renotropic growth jctor. Loss of renal function results in
induction of renotropic growth factor. Detection of the renotro-
pic growth factor in cancer patient sera after removal of cancer-
bearing kidneys proves the presence of functional noncancer-
ous cells in the kidney. These cells carrying renal function
should also be sensitive to renotropic growth factor. To test this
possibility we isolated noncancerous cells from healthy cortex
areas of a cancer-hearing kidney and cultured for assaying their
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Table 1. Effect of uninephrectomized human sera from various renal cancer patients on DNA synthesis in primary human cultured cells of the
kidney
Patient
no. Age Sex Diagnosis
Effect of serum on 3H-thymidine incorporation
Prenephrectomy
(A)a
Postnephrectomy
(B)b
Increased
ratio: (BIA)°
1
2
3
4
5
6
70
70
54
67
65
45
M
M
M
F
M
F
Left-ureteric tumor
Right-pelvic tumor
Left-renal tumor
Left-renal tumor
Right-renal tumor
Right-pelvic tumor
1l,607d
12,705
12,604
12,032
11,448
11,813
14,762
21,308
17,756
32,387
36,537
37,076
1.27
1.68
1.29
2.69
3.19
3.14
a Sera were collected a few days before nephrectomy.
b Five day postuninephrectomized sera were used.
Increased ratio: counts incorporated with nephrectomized serum to counts incorporated with prenephrectomized serum.
d Values are expressed as counts per minute of incorporation of 3H-thymidine into DNA per Petri plate. All cultures were synchronized by 24-hr
serum-free starvation and incubated for 80 mm with 1 Ci/ml 3H-thymidine at 16 hr after a 10% serum addition [71. All cancer patient sera were as-
sayed on primary human kidney cell cultures prepared from the same hydronephrosis kidney.
Table 2. Effect of transplantation donor sera on DNA synthesis in
primary human kidney cultured cells isolated from a noncancerous
cortex area of a cancer-bearing human kidney
Effect of serum on 3H-thymidine incorporation
Prenephrec- Postnephrec- Increased ratio:
Donor Age Sex tomy (A)a tomy (B)b (B/A)c
1 58 F l0,74l' 51,398 4.79
2 52 M 7,418 31,102 4.19
a Sera were collected a few days before nephrectomy.
b Five day postuninephrectomized sera were used.
Increased ratio: counts incorporated with nephrectomized trans-
plantation donor serum to counts incorporated with prenephrectomized
serum.
d Values are expressed as counts per minute of incorporation of 3H-
thymidine into DNA per Petri plate. All cultures were synchronized and
assayed for thymidine incorporation after a 10% serum addition as in
Table 1. Both of these transplantation donor sera were assayed on
noncancerous human kidney cell cultures isolated from the same
cancer-bearing kidney.
growth stimulation by uninephrectomized sera of two kidney
transplantation donors. As shown in Table 2, uninephrecto-
mized sera of both the transplantation donors stimulated their
thymidine incorporation as an index of the growth stimulation
[51. The stimulation of thymidine incorporation into DNA of the
noncancerous cells by the 5-day postnephrectomized sera is
about 4.19- to 4.78-fold increase over that by the prenephrecto-
mized sera. Therefore, we conclude that the noncancerous cells
in cancer-bearing kidneys are quite sensitive to renotropic
growth factor.
Discussion
Fifty percent reduction of renal function by uninephrectomy
causes the growth of the remaining kidney. This renal growth is
controlled by the humoral renotropic growth factor which is
induced by the reduction of renal function. Thus, loss of one
kidney by necrosis or disease should also cause the other
kidney to grow. When we removed a rabbit kidney which
happened to be totally necrotized, no evidence of renotropic
growth factor production after removal of the necrotic kidney
was observed (unpublished data). This observation suggests the
growth of the remaining kidney had already occurred during the
necrotic process which presumably induced renotropic growth
factor.
Partial loss of one kidney by localized diseases including
cancer, tuberculosis, and hydronephrosis [9, 101, should also
induce renotropic growth factor. This humoral growth factor
should stimulate growth of the healthy cells in the disease-
carrying kidney as well as the other intact kidney. We demon-
strated in this paper that the noncancerous cells from a cancer-
bearing kidney are quite sensitive to the renotropic growth
factor for their DNA replication using uninephrectomized trans-
plantation donor sera. However, since the lost proportion of the
renal function is responsible for the amount of renotropic
growth factor produced [6], these localized diseases such as
cancer should induce rather small amounts of the growth factor
which may be produced slowly as the disease infiltrates.
Consequently, the renal growth under these circumstances may
not be visible. Experimentally, the removal of a small portion of
one kidney (up to one third) does not cause recognizable renal
growth if the other kidney is intact [101.
When cancer-bearing kidneys were removed, renotropic
growth-stimulating activities in these patient sera were found.
These growth-stimulating activities vary from patient to patient.
The amount of the growth factor produced is dependent on the
lost proportion of renal function by removal of the cancer-
bearing kidney. Thus, low growth-stimulating activities found
in sera of some uninephrectomized cancer patients indicate that
the functional portion of the removed cancer-bearing kidney
was rather small. Rather low levels of renotropic growth-
stimulating activity in uninephrectomized cancer patient sera
could also be due to the toxic effect of chemotherapeutic drugs.
Dicker, Morris, and Shipolini [11] demonstrated that animals
which received partial hepatectomy and uninephrectomy simul-
taneously do not show kidney growth until almost full recovery
of the liver to its original size and function by regeneration.
Therefore, variation of renotropic growth-stimulating activity in
patient sera could be explained by differences in the extent of
liver toxic effects of chemotherapy on individual patients.
Level of the renotropic growth-stimulating activities varies
somewhat when assayed on different kidney cell cultures be-
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cause these activities are dependent on the relative number of
cell types, for example, epithelial versus fibroblast, in culture
171. Therefore, using a set of primary human kidney cell
cultures from the same origin (that is, hydronephrosis kidney),
we have assayed a group of six cancer patient sera simulta-
neously. Relative levels of these sera are useful for understand-
ing the history and nature of the disease in each patient. In the
case of two healthy kidney transplantation donors, we assayed
renotropic growth-stimulating activities in their uninephrecto-
mized sera simultaneously using a set of noncancerous human
kidney cell cultures derived from a cancer-bearing kidney. The
growth-stimulating activities of these two transplantation do-
nors are very similar and large (4.19- and 4.79-fold) increases
over those of prenephrectomized sera. The fact that two
different transplantation donor sera showed similar and large
increases in growth-stimulating activity assured us the reliabil-
ity and sensitivity of these assays. Furthermore, since we have
shown that the renotropic growth factor does not stimulate
cancerous renal cells [5, 7], even contamination of the cancer-
ous cells in the noncancerous culture should not affect their
sensitivities for the assay of renotropic growth factor. There-
fore, the availability of the noncancerous human kidney cells
from cancer-bearing kidneys and the reliability of the assay
provide a new approach to study various biochemical charac-
teristics of renotropic growth factor and also its role and
production during disease processes.
Summary. We have used two sets of primary human kidney
culture systems for assaying human renotropic growth factor in
day 5 postnephrectomized human sera. The first set of primary
kidney cell cultures was prepared from one hydronephrotic
kidney and used for assaying the renotropic growth stimulating
activity of six kidney cancer patients sera simultaneously. The
level of renotropic growth-stimulating activity varies from
patient to patient. The postnephrectomized sera of three pa-
tients showed rather small (27 to 68%) increase over their
prenephrectomized sera. The postnephrectomized sera of the
remaining three patients showed a much greater (2.69- to 3.19-
fold) increase over their prenephrectomized sera. Variation in
the growth-stimulating activities produced in these uninephrec-
tomized kidney cancer patients is most probably due to differ-
ent levels of renal function loss by removal of the cancer-
bearing kidney. Each cancer-bearing kidney has a different
proportion of healthy kidney region to diseased (nonfunctional)
region. The second set of primary kidney cell cultures was
prepared from a healthy noncancerous region of a cancer-
bearing kidney and used to assay for renotropic growth-stimu-
lating activities in two different unilaterally nephrectomized
kidney transplantation donor sera. Increased levels of growth-
stimulating activity are quite similar and high (4.19- to 4.79-fold
increase above their prenephrectomized sera). These high and
similar assay values of the renotropic growth factor produced in
two healthy humans suggest the sensitivity and reliability of the
assay method with the use of the noncancerous cells from the
cancer-bearing kidney.
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